Lipum AB is a pharmaceutical company based in Umeå that specializes in the development of anti-inflammatory drugs. The company focuses on addressing chronic inflammatory diseases through novel treatment approaches. Lipum AB is engaged in ongoing research and development, aiming to create first-in-class drug candidates that can significantly improve patient outcomes.
One of the company's notable projects includes SOL-116, which has successfully completed Phase 1 clinical trials. Lipum AB is committed to enhancing the quality of life for individuals affected by chronic conditions and aims to support millions who suffer from these diseases. The company regularly provides financial reports and updates, and it maintains an active presence in media and press releases to communicate its progress and developments in the field.
